Status:
COMPLETED
Study of High-Dose Resveratrol in Patients With Stable Ischemic Heart Disease
Lead Sponsor:
S.LAB (SOLOWAYS)
Collaborating Sponsors:
Center for New Medical Technologies, Novosibirsk, Russia
Conditions:
Ischaemic Heart Desease
Eligibility:
All Genders
45-75 years
Phase:
NA
Brief Summary
This 6-month, randomized, double-blind, placebo-controlled pilot study investigates whether high-dose resveratrol (500 mg/day), when added to standard therapy, can improve endothelial function and red...
Detailed Description
This study is a 6-month, double-blind, placebo-controlled pilot randomized clinical trial designed to evaluate the effects of high-dose resveratrol (500 mg/day) on endothelial function and systemic in...
Eligibility Criteria
Inclusion
- Men and women aged 45-75 years.
- Clinically documented stable ischemic heart disease (≥6 months post-myocardial infarction or post-revascularization).
- On stable, guideline-recommended cardiac medications (e.g., statins, beta-blockers, ACE inhibitors).
- Elevated hs-CRP (\>2 mg/L) or impaired endothelial function (FMD \<7%) at baseline (optional enrichment criterion).
- Able and willing to give written informed consent.
Exclusion
- Heart failure with reduced ejection fraction \<30% or New York Heart Association (NYHA) class III-IV.
- Severe hepatic or renal dysfunction.
- Decompensated diabetes (e.g., HbA1c \>10%).
- Current or recent (past 3 months) use of high-dose antioxidant/anti-inflammatory supplements (other than a standard multivitamin).
- Known allergy or intolerance to resveratrol.
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 10 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06914934
Start Date
February 1 2024
End Date
February 10 2025
Last Update
April 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for New Medical Technologies
Novosibirsk, Russia, 630090